For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
The details of the immunogen for this antibody are not available.
This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5,268,486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.
In vivo and in vitro treatment with the 53-6.7 monoclonal antibody effectively depletes CD8 alpha+ cells. The 53-6.7 monoclonal antibody also blocks allogeneic help specific for class I MHC antigens and T cell responses to IL-2.
Our Abpromise guarantee covers the use of ab39853 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use at an assay dependent concentration.
ab154460-Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
|IHC-Fr||Use at an assay dependent concentration.|
|Functional Studies||Use at an assay dependent concentration.
In vivo and in vitro depletion of CD8a+ cells and fractionation of CD8a+ T cells.
|IP||Use at an assay dependent concentration.|
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"